Shanghai Allist Pharmaceuticals Co. Ltd. A
医疗健康 · 生物科技
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.
MARKET 市值 52.92B CNY PE 21.9x
52W ¥78.82 – ¥137.2
EODHD · Q 2026-03-31 · 同步 2026-07-14
QUALITY PEG — 营收 YoY 44.2%
▲ ROE 36.1% 营业利润率 45.7% 净利润率 42.6%
ANALYST 股息率 0.81%